CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea · Delayed Price · Currency is KRW 1,122.00
+22.00 (2.00%)
Jun 12, 2026, 3:30 PM KST
CMG Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 |
Operating Revenue | 110,119 | 105,229 | 99,100 | 93,907 | 82,197 | 58,623 |
Other Revenue | - | - | - | - | - | 0 |
| 110,119 | 105,229 | 99,100 | 93,907 | 82,197 | 58,623 | |
Revenue Growth (YoY) | 13.63% | 6.19% | 5.53% | 14.24% | 40.21% | 17.56% |
Cost of Revenue | 47,546 | 44,352 | 53,456 | 50,315 | 41,446 | 29,738 |
Gross Profit | 62,574 | 60,877 | 45,643 | 43,592 | 40,752 | 28,885 |
Selling, General & Admin | 62,699 | 59,466 | 38,987 | 35,675 | 32,341 | 22,437 |
Research & Development | 964.43 | 1,068 | 1,454 | 2,181 | 3,312 | 1,993 |
Amortization of Goodwill & Intangibles | 981.6 | 1,004 | 1,059 | 787.23 | 499.43 | 404.99 |
Other Operating Expenses | 781.55 | 895.81 | 1,290 | 1,084 | 1,120 | 781.85 |
Operating Expenses | 67,858 | 64,570 | 44,623 | 40,555 | 37,770 | 26,281 |
Operating Income | -5,284 | -3,692 | 1,020 | 3,037 | 2,981 | 2,604 |
Interest Expense | -2,039 | -3,169 | -2,512 | -79.54 | -15.28 | -8.59 |
Interest & Investment Income | 2,331 | 2,938 | 3,130 | 3,752 | 1,963 | 1,100 |
Earnings From Equity Investments | 89.69 | - | 2,620 | 4,308 | - | - |
Currency Exchange Gain (Loss) | 1,764 | -1,291 | 5,634 | 210.08 | 2,054 | 279.83 |
Other Non Operating Income (Expenses) | -1,450 | -1,153 | 3,747 | -1,112 | 64.49 | -581.33 |
EBT Excluding Unusual Items | -4,588 | -6,367 | 13,640 | 10,116 | 7,048 | 3,393 |
Gain (Loss) on Sale of Investments | -416.4 | -316.38 | -9,616 | -3,138 | -7,951 | 534.01 |
Gain (Loss) on Sale of Assets | 23.2 | 10.2 | -11 | -4.09 | -22.76 | 0.5 |
Asset Writedown | -5,165 | -5,165 | -1,133 | -241.97 | -329 | -91.25 |
Pretax Income | -10,146 | -11,839 | 2,880 | 6,731 | -1,255 | 3,837 |
Income Tax Expense | -1,764 | -1,762 | 185.61 | 275.68 | -866.96 | 785.44 |
Earnings From Continuing Operations | -8,383 | -10,077 | 2,695 | 6,455 | -388.14 | 3,051 |
Net Income | -8,383 | -10,077 | 2,695 | 6,455 | -388.14 | 3,051 |
Net Income to Common | -8,383 | -10,077 | 2,695 | 6,455 | -388.14 | 3,051 |
Net Income Growth | - | - | -58.26% | - | - | -49.69% |
Shares Outstanding (Basic) | 136 | 144 | 142 | 139 | 139 | 122 |
Shares Outstanding (Diluted) | 136 | 144 | 539 | 139 | 139 | 122 |
Shares Change (YoY) | -4.59% | -73.24% | 288.03% | - | 14.27% | 11.63% |
EPS (Basic) | -61.42 | -69.87 | 19.00 | 46.48 | -2.79 | 25.10 |
EPS (Diluted) | -61.42 | -69.87 | 5.00 | 46.00 | -3.00 | 25.00 |
EPS Growth | - | - | -89.13% | - | - | -55.12% |
Free Cash Flow | -50,445 | -40,650 | -27,808 | -8,446 | -3,444 | -5,352 |
Free Cash Flow Per Share | -369.63 | -281.84 | -51.60 | -60.81 | -24.80 | -44.03 |
Gross Margin | 56.82% | 57.85% | 46.06% | 46.42% | 49.58% | 49.27% |
Operating Margin | -4.80% | -3.51% | 1.03% | 3.23% | 3.63% | 4.44% |
Profit Margin | -7.61% | -9.58% | 2.72% | 6.87% | -0.47% | 5.21% |
Free Cash Flow Margin | -45.81% | -38.63% | -28.06% | -8.99% | -4.19% | -9.13% |
EBITDA | -2,377 | -610.42 | 4,366 | 5,595 | 5,266 | 4,709 |
EBITDA Margin | -2.16% | -0.58% | 4.41% | 5.96% | 6.41% | 8.03% |
D&A For EBITDA | 2,907 | 3,082 | 3,346 | 2,558 | 2,284 | 2,106 |
EBIT | -5,284 | -3,692 | 1,020 | 3,037 | 2,981 | 2,604 |
EBIT Margin | -4.80% | -3.51% | 1.03% | 3.23% | 3.63% | 4.44% |
Effective Tax Rate | - | - | 6.44% | 4.10% | - | 20.47% |
Advertising Expenses | - | 862.44 | 1,557 | 1,644 | 1,682 | 616.29 |